Results 101 to 110 of about 15,810 (189)
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators ...
Amanda Azevedo Bittencourt +5 more
doaj +1 more source
Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.
Brian D. Johnston (580892) +2 more
core +1 more source
Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens.
Risako Takaya +3 more
doaj +1 more source
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa [PDF]
To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL- producing Escherichia coli and Pseudomonas aeruginosa strains.Methods: A series of ESBL ...
Ortiz de la Rosa, José-Manuel +2 more
core
The activities of ceftolozane-tazobactam and comparator agents against organisms deemed to be the cause of pneumonia among patients hospitalized in the United States during 2013 to 2015 were evaluated.
Mariana Castanheira +4 more
core +1 more source
Clinical characteristics, microbiology data and outcome of patients treated with ceftolozane/tazobactam or ceftazidime/avibactam during the study period.
Juri Katchanov (5095268) +8 more
core +1 more source
Bloodstream infection caused by Pseudomonas aeruginosa with antimicrobial resistance can be difficult to treat. Herein, we investigated antimicrobial susceptibility to major antipseudomonal β-lactams and analyzed the relationship between resistance ...
Mika Murata +7 more
doaj +1 more source
L2 β-lactamase contributes to ceftolozane-tazobactam resistance in <i>Pseudomonas aeruginosa</i>. [PDF]
Garai P +7 more
europepmc +1 more source
Post-Marketing Reporting Patterns of Ceftazidime-Avibactam and Ceftolozane-Tazobactam: Analysis of Adverse Event Reports from EudraVigilance. [PDF]
Gianguzzo VM +8 more
europepmc +1 more source
Ceftolozane/Tazobactam Susceptibility in ESBL-Producing Enterobacterales: Insights from the SMART Program 2020-2022 in China. [PDF]
Wang Y +6 more
europepmc +1 more source

